4basebio and Genezen have expanded a nonexclusive collaboration that will give drug developers access to 4basebio’s synthetic, cell-free DNA for viral vector development and clinical programs.

Under the agreement, Genezen will provide access to 4basebio’s research-use-only, high-quality, and GMP-grade DNA products for programs involving viral vector manufacturing. The companies said the collaboration is intended to provide a more direct path from DNA development to viral vector production for cell and gene therapy developers.

4basebio’s manufacturing process uses enzymatic production rather than bacterial systems, eliminating bacterial backbone sequences and antibiotic resistance genes from the DNA starting material. In adeno-associated virus (AAV) production, the company said its DNA template has produced titers comparable to plasmid DNA while requiring approximately 30% less DNA mass and transfection reagent.

The cell-free production process can also reduce DNA manufacturing timelines compared with conventional plasmid production, according to the announcement. The companies said the approach could help developers reduce material requirements and improve process scalability as programs advance toward clinical manufacturing.

The expanded collaboration follows Genezen’s January agreement with Atsena Therapeutics to provide viral vector manufacturing services for Atsena’s AAV gene therapy programs. The partnership covers clinical and commercial manufacturing support, including activities associated with late-stage development, regulatory readiness, and process validation.